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Impacts
• Antimicrobial resistance among zoonotic and foodborne bacteria represents
a growing threat to public health.
• Increasingly, policies implemented to control antimicrobial resistance are
grounded in statements reflecting moral imperatives and ethical conduct;
these policies may be unsupported by results from quantitative risk
assessments.
• Barriers against, and opportunities for, implementation and adoption of
risk mitigation policies differ among agricultural settings around the world;
therefore, customized and optimized approaches will comprise a varying
mixture of voluntary and mandatory strategies.
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Summary
In addition to the scientific, economic, regulatory and other policy factors that
impact on antimicrobial decision-making in different jurisdictions around the
world, there exist ethical, social and cultural bases for the contemporary use of
these products in animal agriculture. Thus, the use of the word ‘parable’ to
describe the contemporary moral stories that help to guide ethical antimicrobial
use practices and broader policy decisions in animal agriculture is appropriate.
Several of these stories reflect difficult decisions that arise from conflicting moral
imperatives (i.e. both towards animal welfare and towards human health).
Understanding the factors that combine to define the past and present paradigms
of antimicrobial usage is crucial to mapping a path forward. There exist barriers,
as well as opportunities, for advancing scenarios for reducing antimicrobial usage
under a variety of voluntary, regulatory and legal policy frameworks. Any new
approaches will ideally be structured to extend the use of present-day antimicro-
bials into the future, to provide novel alternatives for regulating any newly intro-
duced antimicrobial products so as to maximize their useful life span and to
ensure the optimal use of these products in animal agriculture to protect not only
the health of animals and the interests of animal health/agriculture stakeholders,
but also the human health and the interests of the public at large. A full range of
policy approaches, which span the realm from strictly enforced regulations and
laws to voluntary guidelines and compliance, should be explored with respect to
their risks and benefits in a variety of worldwide settings and in full consideration
of a range of stakeholder values.
Parables
There remains great controversy over the relative contribu-
tion made by antimicrobial use in animal agriculture to
antimicrobial resistance (AMR) in commensal and patho-
genic bacteria; and further, to negative consequences for
human health (Aarestrup et al., 2001, 2010; Hurd et al.,
2004; Hurd, 2006; Alali et al., 2009). Generally speaking,
most concern about resistance is directed at the subset of
antimicrobials known as antibiotics, and especially those
designated as critically important to human medicine by
the World Health Organization (WHO, 2012) and others
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such as the U.S. Food and Drug Administration (FDA,
2003). Despite numerous attempts, it remains exceedingly
difficult to attribute quantitative estimates of absolute or
relative risk to any one particular regimen or type of
antibiotic use, given the complex ecological nature of the
problem. While it remains difficult to directly quantify and
compare risks for the emergence, dissemination and propa-
gation of resistance across the various antimicrobial uses
and among the various livestock hosts, agricultural produc-
tion systems and bacterial species, it is generally accepted
that – overall – more use leads to greater selection pressure
favouring resistance, and therefore, less use favours suscep-
tible bacteria (WHO, 2000). Importantly, even among
those in the agricultural sectors, decisions to use or not use
antimicrobials in certain ways are strongly associated with
individual decision-makers’ perceptions of public health
risk; these risk perceptions in turn are impacted by many
other factors (Jan et al., 2012). In this example, for certain
categories of antibiotic use – such as for therapy and disease
control – beef feedlot veterinarian and producer practices
in the present reflect a strongly held belief that these partic-
ular practices pose little present risk to public health. Thus,
their current behaviours are consistent with their percep-
tions of risk, and future behavioural intentions do not
reflect any substantive changes. The same relation was less
prominent for other uses of antibiotics, such as for growth
promotion, and this differed between veterinarians and
their clients (McIntosh et al., 2009).
The spotlight of public concern is not equally focused on
the four major labelled uses of antimicrobials in animal
agriculture: therapeutic, metaphylactic (or disease control),
prophylactic (or disease prevention) and growth promo-
tion (or feed efficiency). Instead, public concerns about
such uses tend to increase alongside the order in which they
are listed above. Such ordered concerns about the use do
not directly relate to any scientifically derived or published
risk rankings; rather, they tend to derive instead from
moral and ethical ‘litmus tests’ and as such are logically
promulgated using terms such as ‘prudence’ or ‘judicious-
ness’. As a recent example with significant policy implica-
tions, in June of 2010, Dr. Joshua Sharfstein (the then US
FDA deputy commissioner) suggested that antibiotics
should only be used to protect the health of an animal and
not to help it grow faster or more efficiently. Dr. Sharfstein
is quoted as having said during a conference call with
reporters. ‘To preserve the effectiveness, we simply must
use them as judiciously as possible’ (FDA, 2010).
Interestingly, the narrative that emerges concerning the
continued use of antimicrobials in animal agriculture often
invokes more discussion of values than science indicating
that, in the absence of strong scientific evidence – or, per-
haps in spite of it – the emphasis is on moral prescription.
Such a values-based approach to public deliberations and
policymaking is perhaps more often illustrated in the lan-
guage used to enact changes in Europe when compared to
North America. For example, on 30 July 2013, the Euro-
pean Medicines Agency issued an advisory statement sug-
gesting that while ‘colistin [a polymixin] has been used in
veterinary medicine for over 50 years’, and there is ‘. . .no
available evidence on the transfer of resistance to colistin
from animals to man. . .’, the EMA recommends ‘. . .
restricting its use to the treatment of infected animals and
those in contact with them, and to remove all indications
for preventive (or prophylactic) use’ (European Medicines
Agency, 2013). A prominent microbiologist in Birming-
ham, UK, was quoted as stating that ‘The EMA recommen-
dation is “the precautionary principle,” and is
laudable. . .the reality is we should question the use of any
antibacterial agent outside of human medicine until there
is unequivocal evidence showing no effects of animal use
upon human health’ (Cressey, 2013). It seems plausible that
even if the scientific evidence was strong – in either direc-
tion – there would still be an emphasis on moral prescrip-
tion because the purpose of science in this case is to help
society decide what is right and wrong in terms of human
actions; in this case, preserving efficacy for future needs of
human patients stricken with multidrug-resistant Entero-
bacteriaceae. The fact that a lack of scientific evidence alone
cannot provide policy guidance very well serves to ensure
that policymakers pass very swiftly from pointing out the
lack of evidence to saying society needs judicious use.
Around the globe, there exists a wide range of policies,
both written and unwritten, that govern the actual use of
these essential medicines. Those factors that affect agricul-
tural usage patterns range from the glaringly obvious, such
as legislative restrictions and the constraining economics of
animal health and production, to the less obvious, such as
social norms and a sense of moral duty and trust (McIntosh
et al., 2009; Jan et al., 2010); these, in turn, can help to
explain varying usage patterns within any given set of regu-
lations or economic conditions. Adding to the complexity
are the various economies (monetary, political, and moral)
as well as the interests and concerns of a wide range of indi-
viduals and groups ranging from the pharmaceutical, veter-
inary and agricultural production side, through to the
consumer and public health/healthcare advocacy sides
(Dean and Scott, 2005; McIntosh et al., 2009). Setting
boundaries on the limits of discussion by framing the issue
either as a strictly scientific one or else as an entirely eco-
nomic one will necessarily alienate and marginalize persons
and groups with legitimate concerns (Ulrich, 1994; Midg-
ley, 2000). In turn, this will work against furtherance of the
objectives of reducing overall usage of antimicrobials and
decreasing risks to human and animal health. Such
systemic approaches as ‘boundary critique’ (or boundary
analysis) and a plurality of other techniques should be
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employed to examine the likely impacts and effects of mar-
ginalizing various stakeholder viewpoints at each step along
the way (Midgley, 2000, 2006; Midgley and Pinzon, 2011,
2013). Less inclusive policy decision processes are unlikely
to result in sustainable and defensible long-term solutions
and to sustain conflicts far beyond their expected life span.
Policy
The process by which new animal drugs are approved, or
existing drugs are re-evaluated for continued or expanded
approval, is not consistent throughout the world, whether
it be in the so-called ‘developed world’ or in the ‘develop-
ing world’. Further, there are vast differences in the
‘post-approval’ regulatory environment the world over,
leading to very real barriers to changes in marketing,
prescribing, sales and use of these products. For illustrative
purposes, the following discussions will be restricted to a
comparison and contrast of European and the U.S. experi-
ences over the past decade or so.
The European ban on the use of antibiotics as growth
promoters (AGPs) took effect on 1 January 2006 (Aarest-
rup et al., 2008) and was arguably largely based on the pre-
cautionary principle. This move followed other regional
country leads like Sweden (mid 1980s) and a series of
somewhat voluntary bans in Denmark (from 1996
onwards). The Danes, in particular, have been vigorous in
tracking the effects of the ban (preceded by profit restric-
tions on veterinarians) on each of sales of antibiotics, resis-
tance among bacteria and production of pigs in particular
(Aarestrup et al., 2001, 2010; Aarestrup, 2012). Results
concerning the overall effects of the ban in other European
countries are still being compiled; however, there is general
agreement that with reductions in AGP use at least some
‘substitution’ of therapeutic and prophylactic products has
likely taken place. Debates over any subsequent increases in
the levels of critically important antimicrobials (CIAs) used
as therapy, in place of AGPs or prophylaxis, are more hotly
contested (Doyle et al., 2013).
In the United States, a major shift in the way that new
animal antimicrobials are approved, labelled and regulated
occurred in 1997 when the FDA issued prohibition orders
against the extra-label use of fluoroquinolones and glyco-
peptides in food-producing animals (Doyle et al., 2013). At
the time, the FDA was revisiting rules on the ways in which
veterinarians could prescribe products in an ‘extra-label’
manner. One of the outcomes of this process was the iden-
tification of certain products for which prohibition orders
would be issued against extra-label drug use (ELDU). For
fluoroquinolones and glycopeptides, these orders were for
the first time directly tied to microbial safety, in the form
of resistance avoidance, as opposed to the usual (at the
time) concerns over residues or toxicological endpoints.
Note that no actual changes were made to the labelled (flu-
oroquinolone) or non-labelled (glycopeptide) products;
rather, these orders focused on restricting the subset of
conditions under which veterinarians were operating that
allowed their prescribing practices to differ from the prod-
uct label. More recently, in April of 2012, another class of
antibiotics (cephalosporins) was added to the list of
prohibited extra-label drugs; albeit, with some notable
exemptions allowing for minor species and also the same
for non-indicated dose, duration and route of administra-
tion in approved species (FDA, 2012a).
Soon after the 1997, US extra-label use, bans for fluor-
oquinolones and glycopeptides were put in place, a com-
pletely new approach to addressing microbial safety of new
antimicrobial drugs ensued in the form of Guidance for
Industry (GFI) 152 (FDA, 2003). The philosophy underly-
ing this document will be discussed in the next section;
however, perhaps of greater interest than the document
itself is an intriguing process that can be found through a
content and narrative analysis of the transcribed minutes of
the public hearings that preceded the publication of the
GFI 152 document (Dean and Scott, 2005). Chief among
the deliberations was a fierce debate over the actual form
that any risk assessment should take. Attention focused on
the divisive interactions between agricultural, veterinary
and pharmaceutical companies on one side and the U.S.
FDA on the other. However, this belies the fact that what
appeared on the surface to be an antagonistic public dis-
course was actually a process capable of simultaneously
legitimizing the roles of the FDA as the official arbiter of
policy on antimicrobial use in animal agriculture and as a
protector of the public welfare, as well as the role of phar-
maceutical companies as the producers of safe and effective
products necessary for the protection of animal health and
public well-being.
Implicit in the earlier statements attributed to FDA dep-
uty commissioner Dr. Sharfstein are both ethical codes (i.e.
defining appropriate professional conduct and practice) and
moral duties (to preserve antibiotic effectiveness for others
– be they humans or animals –who may need them in the
future). It is not coincidental that GFI #209, published in
2012, which directs the pharmaceutical industry to volun-
tarily withdraw their growth promotion labels by December
of 2016, uses much of the same language of ethical (judi-
cious) practice to motivate its implementation (FDA,
2012b). This document leads further to document GFI #213
– which was published recently (FDA, 2013) – that allows
for relabelling of some feed grade antimicrobial formula-
tions and dosages for prevention and control purposes. The
veterinarian, who is bound by codes of professional ethical
conduct, has also been brought more formal into the deci-
sion-making process for all situations in which antibiotics
are to be used in feedstuffs for food-producing animals.
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These two documents stand in contrast to GFI #152 – dis-
cussed above – which, while motivated by many of the same
moral concerns about future effectiveness, retains a modi-
cum of scientific control and judgment over the process of
new animal drug approvals by way of a qualitative risk
assessment matrix (FDA, 2003; Dean and Scott, 2005; Hurd,
2006; Doyle et al., 2013). That said, prudence overrides all
other factors (such as release and exposure risk, and even
indication) in the GFI 152 matrix simply by way of an anti-
biotic being designated as ‘critically important’, resulting in
the consequence of resistance being critically important and
the risk being coded as ‘high’ (FDA, 2003 – page 21).
There are several good examples of where regions,
countries, agricultural industries, and individual farming
operations – whether via voluntary or involuntary action –
have achieved measureable reductions in antimicrobial
usage in veterinary medicine. As mentioned earlier, a Euro-
pean ban on antibiotic growth promoters (the use of anti-
biotics in animal feeds, often at so-called ‘subtherapeutic’
concentrations, to increase the growth rate and feed effi-
ciency of animals) has been in place since January, 2006
(Aarestrup et al., 2008). At national levels, Sweden (1986)
and Denmark (1999) are perhaps the longest standing
where over a period of 15+ years, successively more
restricted use (in volume and by class of antimicrobials)
has been successfully introduced in veterinary medicine
and animal agriculture. Importantly, these bans have also
been suggested to have resulted in reductions in resistance,
especially to glycopeptides and macrolide resistances (Aa-
restrup et al., 2001). Recently, in the Netherlands, a reduc-
tion of 50–70% of veterinary usage has been imposed and
is expected to be achieved over the next 3- to 5-year period
(Wagenaar, J., personal communication). However, the
number of regions and countries where regulatory action
has been introduced and deemed successful in achieving its
stated goals is very limited. Worldwide, antimicrobial use
in animal production is largely unregulated and unre-
stricted. Understanding the barriers and opportunities for
change in antimicrobial use that exist worldwide, and the
unique aspects of each region that could best lead to
improvements in antimicrobial practices and regulations,
would be useful for aiding international agencies such as
WHO, the Food and Agricultural Organization of the Uni-
ted Nations (FAO) and the World Organization for Animal
Health (OIE) to better address and achieve many of their
stated development goals and health targets.
At industry and farm levels, there are instances where
either ‘natural experiments’ have been observed (Dutil
et al., 2010) or farms have elected to shift to either antibi-
otic-free, or certified organic (Bunner et al., 2007; Keelara
et al., 2013) operations, respectively. In Dutil et al. (2010),
a sharp reduction in ceftiofur resistance among Escherichia
coli and Salmonella Heidelberg isolates in broilers and on
broiler meat was observed following an industry-wide vol-
untary cessation of in ovo injections of ceftiofur in broiler
hatcheries. Concurrently, levels of ceftiofur resistance also
dropped in human cases of salmonellosis attributed to the
S. Heidelberg serovar. It is incredibly rare that such a series
of events was observed in the first place, and that an inter-
vention could have such a dramatic result. It seems highly
improbable that such a reduction in resistance would have
been seen with longer-standing products such as tetracy-
cline, streptomycin and sulphonamide resistances if those
products had instead been withdrawn from use. Ceftiofur is
relatively new, and coresistance in the case of S. Heidelberg
was uncommon and therefore not coselected by tetracycline
use. All of this created a ‘perfect storm’ of opportunity to
observe a dramatic reduction in resistance following cessa-
tion of use.
In contrast, most studies of antibiotic-free versus con-
ventional agricultural productions do not show such dra-
matic differences. Of course, practices vary by animal type
and operation. Data from Bunner et al. (2007), conducted
on E. coli, suggest that for long-standing drugs such as tet-
racyclines, there is little meaningful difference in resistance.
However, for more recently reduced products, there can be
substantive differences. In addition, Keelara et al. (2013)
have shown that besides selecting for lower resistance
among Salmonella enterica, there can also be a lowered
overall prevalence of Salmonella on ABF versus conven-
tional farms.
As has been noted by Doyle et al. (2013), the U.S.
National Antimicrobial Resistance Monitoring System
(NARMS) has been in place for over 15 years and holds a
wealth of useful information that only increases in value
over time. Several trends are apparent, including an
increase in resistance to beta-lactams among Enterobacteri-
aceae. On the other hand, resistance to several antibiotic
classes, including critically important classes such as fluor-
oquinolones, are exhibiting very low levels of resistance in
Salmonella, suggesting that something appears to be
working, policy-wise.
Major problems in scientific inquiry do not arise solely
with the inappropriate choice of study design or method;
instead, the points of reference of the inquirer can readily
direct – or misdirect – the interpretation of results. Some
say the data speak for themselves, except that they cannot;
they always end up being examined and filtered through the
lens of the observer (Von Foerster, 1979; Von Glasersfeld,
1985; Maturana, 1988; Hollway, 1989) – and this observer
may be a scientist, journalist, advocate, policymaker or lay
person. The science of antimicrobial resistance is no differ-
ent than other fields of study; it is frequently possible for
two scholars to examine the same data and to come to dif-
ferent conclusions. While the institution of science uses
mechanisms such as hypothesis testing to eliminate multiple
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interpretations, and research communities tend to self-select
the interpretations they find most persuasive, in principle a
new and compelling interpretation of any piece of evidence
may be just around the corner (Popper, 1972). The reasons
for this are multiple, just like the interpretations of evidence,
which provides a reason for soliciting a plurality of disci-
plines, methods and stakeholder values in setting research
agendas and regulatory frameworks, as has been consistently
advocated by Midgley (2000, 2006). Acknowledging multi-
ple interpretations does not lead to decision paralysis if sys-
temic processes are used to engage with stakeholders to
support learning, dialogue on evidence, better mutual
understanding and the identification of new possibilities for
action (Checkland and Poulter, 2006).
An apparent paradox is illustrated in a recent series of
papers on AMR in cattle (Lowrance et al., 2007; Platt et al.,
2008; Cottell et al., 2013; Kanwar et al., 2013, 2014); these
point to the pitfalls inherent in interpreting data from only
a single viewpoint. Traditionally, the measurable and
reported endpoint of interest for monitoring and surveil-
lance of enteric bacteria has been the prevalence of pheno-
typic (or genotypic) resistance traits among isolates at the
bacterial population level. At rest (or equilibrium) – mean-
ing when the bacterial ecosystem is undisturbed by antimi-
crobial selection pressures – prevalence alone can be a
reasonable estimate of resistance load; albeit, complicated
by a multivariate set of endpoints (e.g. up to 15 antimicro-
bials on a broth microdilution plate, with many more
genetic elements to explain each resistance). However,
when the system is disturbed by antimicrobial use (see
Lowrance et al., 2007), the denominators of total bacteria
change dramatically, sometimes giving highly biased
estimates of the actual prevalence or count of resistant
bacteria.
In the aforementioned series of papers, it became clear
that relying solely on phenotypic or genotypic prevalence
among isolates was insufficient for understanding the true
bacterial dynamics and microbial ecology at play in the
intestine of treated and untreated animals. As a result of
using only one ‘lens’ to view a single endpoint (Platt et al.,
2008: ceftiofur resistance among E. coli), it was observed
that chlortetracycline in feed was associated with a reduc-
tion in ceftiofur resistance. To protect against ceftiofur
resistance, it initially appeared that one could select
against resistance to one antimicrobial by using another.
This, despite the clear mechanistic potential for coselection
given that both tet(A) and blaCMY-2 genes were known to
be present on the same IncA/C plasmid. In subsequent
work by Cottell et al. (2012) and Kanwar et al. (2013,
2014), the authors identified additional explanations for
the apparent sparing effect on ceftiofur resistance, simply
by widening the view of their lens to include additional
qualitative and quantitative endpoints. The take-home
message should be that an imprudent choice of a single
outcome measure for a scientific inquiry into AMR can
serve to make interpretation of study results difficult at
best, and biased at worst.
One final word of caution is in order, in fitting with the
theme of paradox. Many individuals and companies are
clamouring for ‘alternatives’ to antibiotics in the face of a
changing regulatory landscape. In particular, metals such as
copper (Cu) and zinc (Zn), which are known to have anti-
bacterial properties and also to promote animal growth at
higher than nutrient requirements, have been substituted
for antibiotics, often in those countries where antibiotic
growth promoters have been banned. It is becoming clear
(see Amachawadi et al., 2011; Cavaco et al., 2011), that
coselection of antibiotic resistance along with transferable
metal resistance cohoused on the same plasmid(s) is mak-
ing the design and selection of ‘alternatives’ fraught with
difficulty. For copper and zinc, these have thus far been
seen to play out among Enterococcus spp. (macrolide and
tetracycline resistance) and Staphylococcus aureus (methicil-
lin and tetracycline resistance), respectively.
A 2012 conference held at the headquarters of the World
Organization for Animal Health (OIE) in Paris highlighted
a wide range of alternatives to antibiotics, each holding
some promise for success (United States Department of
Agriculture, 2012). These include the metals, host antimi-
crobial peptides (recombinant), essential oils, immuno-
modulants, among others. It should be remembered that
any product that disrupts bacterial populations will neces-
sarily select for those that are able to cope. If such mecha-
nisms can be mobilized genetically, they will be.
Approaches that are holistically designed and assessed as to
adverse outcomes, especially when minimizing selection
pressures for bacteria resistant to critically important anti-
microbials, should actively be pursued.
Regardless of the setting, it seems apparent that moving
forward science will continue to play a valued and expand-
ing role by informing debates and policy decisions over the
design of the most appropriate regulations and guidance
for antimicrobial use in animal agriculture. However, it is
likewise apparent that such debates will be fuelled – on one
side – by a sense of moral outrage over the perceived
squandering of a precious resource that saves lives, and –
on the other side – by a strongly felt sense of legitimacy in
using products previously proven to be safe via science, reg-
ulatory approval, and ongoing scrutiny, rather than by any
sense that new scientific knowledge will further enlighten
stakeholders on either side of the issue. Continued vigilance
is needed to ensure that multiple and varied stakeholder
values are considered as much as is practicable when setting
policy, and that common ground is identified wherever
possible so as to avoid protracted conflicts in this area. In
summary, parables can provide the moral compass to guide
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ethical practice for wicked problems such as antimicrobial
resistance; that is, so long as science continues to inform
the most effective policy decisions.
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